+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Ornithine Transcarbamylase Deficiency Pipeline Analysis and Outlook, 2019

  • PDF Icon


  • 40 Pages
  • May 2019
  • Region: Global
  • VPA Research
  • ID: 4772498
Ornithine Transcarbamylase Deficiency pipeline

Ornithine Transcarbamylase Deficiency pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Ornithine Transcarbamylase Deficiency R and D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Ornithine Transcarbamylase Deficiency report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Ornithine Transcarbamylase Deficiency as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Ornithine Transcarbamylase Deficiency with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Ornithine Transcarbamylase Deficiency pipeline Profiled in detail

Key players actively participating in Ornithine Transcarbamylase Deficiency pipeline are profiled along with their R&D progress in Ornithine Transcarbamylase Deficiency treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Ornithine Transcarbamylase Deficiency pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Ornithine Transcarbamylase Deficiency treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Ornithine Transcarbamylase Deficiency pipeline and treatment landscape

  • Complete list of drug candidates from discovery to pre-registration phases are analyzed

  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio

  • Detailed drug profiles of Ornithine Transcarbamylase Deficiency pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed

  • Research and Development progress and trial details, results wherever available, are also included in the Ornithine Transcarbamylase Deficiency pipeline study

  • All recent news and developments related to Ornithine Transcarbamylase Deficiency drugs are provided

Table of Contents

1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019
2. Ornithine Transcarbamylase Deficiency Disease Overview
3. Ornithine Transcarbamylase Deficiency Research and Development Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019
4. Ornithine Transcarbamylase Deficiency Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History
5. Ornithine Transcarbamylase Deficiency Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History
6. Company Profiles
6.1. Ornithine Transcarbamylase Deficiency companies
6.1.1 Business Profile
6.1.2. Pipeline Products
6.1.3. Ornithine Transcarbamylase Deficiency Activities
7. Recent News Landscape
8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services

Companies Mentioned

  • Arcturus Therapeutics Ltd

  • Lucane Pharma SA

  • Promethera Biosciences SA

  • Selecta Biosciences Inc

  • Translate Bio Inc

  • Ultragenyx Pharmaceutical Inc